Fig. S1. Illustration showing the in vitro angiogenesis model.

Fig. S2. Immunoexpression of TP and VEGF in primary carcinosarcoma.

Fig. S3. Human TSP-1 gene expression in HUVEC (A) and FU-MMT-1 cells (B).

Fig. S4. Results of the cytotoxicity assay in HUVEC.

Fig. S5. Changes in sonographic vascular density at week 8.

Fig. S6. Anti-angiogenic effects determined by LDPI.

Table S1. Laser Doppler flowmeter analysis of FU-MMT-1 xenografts at week 4 of treatment.

Data S1.In vitro tube formation assay; assessment of human TSP-1 gene expression in FU-MMT-1 cells and HUVEC; cytotoxicity assay; contrast-enhanced color Doppler US; laser Doppler perfusion imaging; and western blot analysis.

CAS_1998_sm_DataS1.doc36KSupporting info item
CAS_1998_sm_fS1.tif240KSupporting info item
CAS_1998_sm_fS3B.tif178KSupporting info item
CAS_1998_sm_fS4.tif205KSupporting info item
CAS_1998_sm_fS5A-D.tif2056KSupporting info item
CAS_1998_sm_fS5E.tif213KSupporting info item
CAS_1998_sm_fS6A-F.tif3526KSupporting info item
CAS_1998_sm_fS2A-D.tif3875KSupporting info item
CAS_1998_sm_fS3A.tif228KSupporting info item
CAS_1998_sm_tS1.xls22KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.